Advancing Targeted Treatments for Neurodegenerative Diseases
- Neurological diseases currently represent the leading cause of ill health and disability on a global scale.
- A May 30, 2026, report in The Lancet indicates that while some progress has been made in treating specific neurological conditions, neurodegenerative biology continues to be largely intractable.
- The difficulty in treating these conditions is particularly evident in cases of Alzheimer's disease, Parkinson's disease and motor neuron disease.
Neurological diseases currently represent the leading cause of ill health and disability on a global scale.
A May 30, 2026, report in The Lancet indicates that while some progress has been made in treating specific neurological conditions, neurodegenerative biology continues to be largely intractable.
The difficulty in treating these conditions is particularly evident in cases of Alzheimer’s disease, Parkinson’s disease and motor neuron disease.
This lack of progress in neurodegenerative diseases stands in contrast to developments in other areas of neurology. For example, substantial progress has been achieved in modulating the inflammatory component of multiple sclerosis.
Scientific advances have since deepened the understanding of neurodegenerative pathobiology. This increased knowledge has enabled the targeted identification of candidate treatments that are considered mechanistically plausible.
To accelerate the development of these treatments, there is a focus on implementing multi-arm multi-stage platform trials for neurological diseases.